Leading Companies Enhancing Their Presence in the Viral Vectors and Plasmid DNA Market

The viral vectors and plasmid DNA industry is on the brink of significant expansion, driven by advances in gene therapy and immunotherapy. This market is set to witness robust growth fueled by technological innovations and increasing demand across various medical applications. Let's explore the current market size, key players, prevailing trends, and important market segments shaping the future of this dynamic field.

Projected Market Size and Growth Trajectory for Viral Vectors and Plasmid DNA
The viral vectors and plasmid DNA market is anticipated to experience substantial growth in the coming years, reaching a valuation of $1.89 billion by 2030. This reflects a compound annual growth rate (CAGR) of 6.6% during the forecast period. The surge is largely driven by advancements in clinical-grade and GMP plasmid DNA production, expanding use of viral vectors in cancer and infectious disease therapies, increased investment in gene therapy, and rising demand for immunotherapy solutions. Additionally, novel vector platforms such as AAV (Adeno-Associated Virus) and lentiviral vectors are being increasingly adopted, further fueling market expansion. Key trends expected to dominate include the growing utilization of plasmid DNA and viral vectors in gene therapy, enhancements in GMP-grade plasmid DNA manufacturing, intensive research into novel viral vectors, and the integration of these technologies in vaccine development and immunotherapy.

Download a free sample of the viral vectors and plasmid dna market sample:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3245&type=smp&utm_source=OpenPR&utm_medium=Paid&utm_campaign=Apr_PR

Driving Forces Behind Growth in the Viral Vectors and Plasmid DNA Market
One of the primary factors propelling the viral vectors and plasmid DNA market is the intensifying demand for effective gene therapies targeting a wide range of diseases, including cancer and genetic disorders. As gene therapy emerges as a transformative treatment approach, the need for reliable viral vectors and high-quality plasmid DNA is escalating.
In parallel, increased funding and investments from both public and private sectors are fueling research and development activities. These investments are accelerating innovations in vector design and production, enabling more efficient and safer gene delivery methods, which in turn are boosting market expansion.

Leading Companies Driving Innovation in the Viral Vectors and Plasmid DNA Industry
Several prominent companies play a pivotal role in shaping the viral vectors and plasmid DNA market. Among the key players are FUJIFILM Diosynth Biotechnologies, FinVector Vision Therapies, Lonza Group AG, Cobra Biologics and Pharmaceutical Services, Brammer Bio, Kaneka Corporation, Cell and Gene Therapy Catapult, VGXI Inc., MassBiologics, Sanofi, Spark Therapeutics, UniQure NV, Thermo Fisher Scientific, VIROVEK, SIRION Biotech GmbH, ALDEVRON, Oxford BioMedica, PlasmidFactory GmbH & Co. KG, Biovian Oy, BioReliance Corporation, 4D Molecular Therapeutics, Renova Therapeutics, Shenzhen SiBiono GeneTech Co., Vigene Biosciences Inc., Novasep, Genzyme Corporation, Oxford Gene Technology, Richter-Helm, MolMed, Merck KGaA Inc., Catalent Inc., WuXi AppTec, GenScript Biotech Corporation, Eurogentec, and Creative Biogene.
A notable acquisition in this landscape occurred in January 2023, when Moderna Inc., a US-based biotechnology firm, purchased OriCiro Genomics for $85 million. This move is expected to expedite Moderna's pipeline development by enhancing capabilities in plasmid DNA synthesis and amplification, essential for producing messenger RNA (mRNA). OriCiro Genomics specializes in cell-free systems for assembling and amplifying circular DNA molecules, including plasmids and viral vectors.

View the full viral vectors and plasmid dna market report:
https://www.thebusinessresearchcompany.com/report/viral-vectors-and-plasmid-dna-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Apr_PR

Emerging Innovations Highlighted in the Viral Vectors and Plasmid DNA Market
Leading market participants are increasingly focusing on launching cutting-edge products such as helper plasmids to strengthen their positions. Helper plasmids play a crucial role in producing viral vectors, especially adeno-associated viral vectors (AAV), which are widely applied in gene therapy.
For example, in March 2023, Charles River Laboratories International Inc., a US pharmaceutical company, introduced an off-the-shelf pHelper plasmid designed to accelerate the development of AAV-based gene therapies. This product is part of their comprehensive contract development and manufacturing organization (CDMO) offerings, aiming to simplify the complex supply chains involved in viral vector packaging and gene therapy manufacturing.

Segmentation and Market Share Analysis of Viral Vectors and Plasmid DNA
This market is categorized across multiple dimensions:
1) By Product Type: Plasmid DNA and Viral Vectors
2) By Disease Focus: Infectious Diseases, Genetic Disorders, Cancer, and Other Diseases
3) By Application: Gene and Cancer Therapies, Viral Infection Treatments, Immunotherapy, Formulation Development, and Additional Applications
4) By End Users: Research Institutes and Biopharmaceutical/Pharmaceutical Companies

Further breakdown includes:
- For Plasmid DNA: Research-Grade Plasmid DNA, Clinical-Grade Plasmid DNA, and GMP (Good Manufacturing Practice) Plasmid DNA
- For Viral Vectors: Adenoviral Vectors, Lentiviral Vectors, AAV Vectors, Retroviral Vectors, and Vesicular Stomatitis Virus (VSV) Vectors

These segments provide a comprehensive understanding of market dynamics and help pinpoint areas of opportunity for innovation and investment.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.